Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction
ChemMedChem · 2026
DOI: 10.1002/cmdc.70311 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Timoteo Delgado-Maldonado and 5 co-authors. Institution: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México. Major MEDLINE topics: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Antiviral Agents, Angiotensin-Converting Enzyme 2. 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional, SIP, IPN.
Abstract (original language)
Coronavirus disease (COVID‐19) remains a global health concern due to its high mortality and morbidity. In this study, we combined ligand‐based pharmacophore modeling (LBPM) with structure‐based virtual screening (SBVS) to identify novel inhibitors targeting the SARS‐CoV‐2 spike protein. Ligands from the MolPort database were screened via docking and molecular dynamics simulations at the receptor‐binding domain (RBD). Four compounds showed promising docking scores (–8.7 to –6.4 kcal/mol) and dynamic stability (root mean square deviation < 5 Å). In vitro assays confirmed that compounds C3 (IC 50 = 0.03 µM) and C4 (IC 50 = 10.4 µM) effectively inhibited spike–ACE2 binding with low cytotoxicity (CC 50 > 100 µM). These findings show the efficacy of the LBPM technique and highlight 1H‐pyrazol‐5‐ol derivatives as potential building blocks for developing new antiviral agents against SARS‐CoV‐2.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
- School of Integrative Biological and Chemical Sciences (SIBCS) & School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, Texas, USA.
- Laboratorio de estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Oaxaca, México.
ORCID profiles: Gildardo Rivera
Funding
- Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional
- SIP, IPN
Cite
APA
Delgado-Maldonado, T., Vargas-Salas, G., Bandyopadhyay, D., Moreno-Rodríguez, A., Ortiz-Pérez, E., & Rivera, G. (2026). Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction. ChemMedChem. https://doi.org/10.1002/cmdc.70311
Vancouver
Delgado-Maldonado T, Vargas-Salas G, Bandyopadhyay D, Moreno-Rodríguez A, Ortiz-Pérez E, Rivera G. Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction. ChemMedChem. 2026. doi:10.1002/cmdc.70311
BibTeX
@article{DelgadoMaldonado2026,
author = {Delgado-Maldonado, Timoteo and Vargas-Salas, Gilberto and Bandyopadhyay, Debasish and Moreno-Rodríguez, Adriana and Ortiz-Pérez, Eyra and Rivera, Gildardo},
title = {Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70311}
}
EUVIMED